Genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and health outcomes: a drug-target Mendelian randomization study and a phenome-wide association study.
Humans
Apolipoproteins B
/ genetics
Asialoglycoprotein Receptor
/ antagonists & inhibitors
Calcium
Cholelithiasis
Coronary Artery Disease
/ genetics
Diabetes Mellitus, Type 2
/ drug therapy
Genome-Wide Association Study
Insulin-Like Growth Factor I
Mendelian Randomization Analysis
Polymorphism, Single Nucleotide
Risk Factors
Triglycerides
ASGR1 inhibitors
All-cause mortality
Cardiovascular disease
Mendelian randomization
Phenome-wide association study
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
03 07 2023
03 07 2023
Historique:
received:
04
03
2023
accepted:
19
05
2023
medline:
5
7
2023
pubmed:
4
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Asialoglycoprotein receptor 1 (ASGR1) is emerging as a potential drug target to reduce low-density lipoprotein (LDL)-cholesterol and coronary artery disease (CAD) risk. Here, we investigated genetically mimicked ASGR1 inhibitors on all-cause mortality and any possible adverse effects. We conducted a drug-target Mendelian randomization study to assess genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and 25 a priori outcomes relevant to lipid traits, CAD, and possible adverse effects, i.e. liver function, cholelithiasis, adiposity and type 2 diabetes. We also performed a phenome-wide association study of 1951 health-related phenotypes to identify any novel effects. Associations found were compared with those for currently used lipid modifiers, assessed using colocalization, and replicated where possible. Genetically mimicked ASGR1 inhibitors were associated with a longer lifespan (3.31 years per standard deviation reduction in LDL-cholesterol, 95% confidence interval 1.01 to 5.62). Genetically mimicked ASGR1 inhibitors were inversely associated with apolipoprotein B (apoB), triglycerides (TG) and CAD risk. Genetically mimicked ASGR1 inhibitors were positively associated with alkaline phosphatase, gamma glutamyltransferase, erythrocyte traits, insulin-like growth factor 1 (IGF-1) and C-reactive protein (CRP), but were inversely associated with albumin and calcium. Genetically mimicked ASGR1 inhibitors were not associated with cholelithiasis, adiposity or type 2 diabetes. Associations with apoB and TG were stronger for ASGR1 inhibitors compared with currently used lipid modifiers, and most non-lipid effects were specific to ASGR1 inhibitors. The probabilities for colocalization were > 0.80 for most of these associations, but were 0.42 for lifespan and 0.30 for CAD. These associations were replicated using alternative genetic instruments and other publicly available genetic summary statistics. Genetically mimicked ASGR1 inhibitors reduced all-cause mortality. Beyond lipid-lowering, genetically mimicked ASGR1 inhibitors increased liver enzymes, erythrocyte traits, IGF-1 and CRP, but decreased albumin and calcium.
Sections du résumé
BACKGROUND
Asialoglycoprotein receptor 1 (ASGR1) is emerging as a potential drug target to reduce low-density lipoprotein (LDL)-cholesterol and coronary artery disease (CAD) risk. Here, we investigated genetically mimicked ASGR1 inhibitors on all-cause mortality and any possible adverse effects.
METHODS
We conducted a drug-target Mendelian randomization study to assess genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and 25 a priori outcomes relevant to lipid traits, CAD, and possible adverse effects, i.e. liver function, cholelithiasis, adiposity and type 2 diabetes. We also performed a phenome-wide association study of 1951 health-related phenotypes to identify any novel effects. Associations found were compared with those for currently used lipid modifiers, assessed using colocalization, and replicated where possible.
RESULTS
Genetically mimicked ASGR1 inhibitors were associated with a longer lifespan (3.31 years per standard deviation reduction in LDL-cholesterol, 95% confidence interval 1.01 to 5.62). Genetically mimicked ASGR1 inhibitors were inversely associated with apolipoprotein B (apoB), triglycerides (TG) and CAD risk. Genetically mimicked ASGR1 inhibitors were positively associated with alkaline phosphatase, gamma glutamyltransferase, erythrocyte traits, insulin-like growth factor 1 (IGF-1) and C-reactive protein (CRP), but were inversely associated with albumin and calcium. Genetically mimicked ASGR1 inhibitors were not associated with cholelithiasis, adiposity or type 2 diabetes. Associations with apoB and TG were stronger for ASGR1 inhibitors compared with currently used lipid modifiers, and most non-lipid effects were specific to ASGR1 inhibitors. The probabilities for colocalization were > 0.80 for most of these associations, but were 0.42 for lifespan and 0.30 for CAD. These associations were replicated using alternative genetic instruments and other publicly available genetic summary statistics.
CONCLUSIONS
Genetically mimicked ASGR1 inhibitors reduced all-cause mortality. Beyond lipid-lowering, genetically mimicked ASGR1 inhibitors increased liver enzymes, erythrocyte traits, IGF-1 and CRP, but decreased albumin and calcium.
Identifiants
pubmed: 37400795
doi: 10.1186/s12916-023-02903-w
pii: 10.1186/s12916-023-02903-w
pmc: PMC10318778
doi:
Substances chimiques
Apolipoproteins B
0
ASGR1 protein, human
0
Asialoglycoprotein Receptor
0
Calcium
SY7Q814VUP
Insulin-Like Growth Factor I
67763-96-6
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
235Informations de copyright
© 2023. The Author(s).
Références
J Biol Chem. 2021 Oct;297(4):101177
pubmed: 34508778
Elife. 2019 Jan 15;8:
pubmed: 30642433
Atherosclerosis. 2020 Aug;306:15-21
pubmed: 32679274
J Clin Epidemiol. 2019 Sep;113:123-128
pubmed: 31121303
Nature. 2021 Dec;600(7890):675-679
pubmed: 34887591
Nat Genet. 2015 Oct;47(10):1121-1130
pubmed: 26343387
Nat Genet. 2021 Jun;53(6):840-860
pubmed: 34059833
JAMA Cardiol. 2016 Sep 1;1(6):692-9
pubmed: 27487401
Nat Rev Mol Cell Biol. 2018 Feb;19(2):121-135
pubmed: 28974774
BMC Med. 2021 Jun 30;19(1):151
pubmed: 34187478
Am J Hum Genet. 2022 May 5;109(5):767-782
pubmed: 35452592
Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
BMJ. 2011 Feb 15;342:d548
pubmed: 21325005
J Am Heart Assoc. 2022 Jun 21;11(12):e024248
pubmed: 35699189
Gastroenterology. 2020 Apr;158(5):1300-1312.e20
pubmed: 31884074
Eur J Epidemiol. 2017 May;32(5):377-389
pubmed: 28527048
J Am Coll Cardiol. 2014 May 27;63(20):2121-2128
pubmed: 24657701
PLoS Genet. 2021 Nov 11;17(11):e1009891
pubmed: 34762653
Genetics. 2018 Apr;208(4):1397-1408
pubmed: 29429966
Eur J Hum Genet. 2015 Apr;23(4):523-9
pubmed: 25074467
Prev Med. 2016 Oct;91:351-355
pubmed: 27609746
PLoS Genet. 2020 Apr 20;16(4):e1008720
pubmed: 32310995
Gastroenterology. 2004 May;126(5):1287-92
pubmed: 15131789
Nature. 2022 Aug;608(7922):413-420
pubmed: 35922515
Genome Med. 2022 Jun 14;14(1):63
pubmed: 35698167
Sci Rep. 2016 Dec 20;6:38813
pubmed: 27996050
Annu Rev Biochem. 1982;51:531-54
pubmed: 6287920
Int J Epidemiol. 2023 Jun 6;52(3):921-931
pubmed: 36367831
PLoS Genet. 2014 May 15;10(5):e1004383
pubmed: 24830394
Nat Rev Endocrinol. 2018 Aug;14(8):452-463
pubmed: 29904174
Sci Rep. 2017 Feb 14;7:42691
pubmed: 28195141
Hepatology. 2005 Apr;41(4):690-5
pubmed: 15789367
Wellcome Open Res. 2021 Jan 28;6:16
pubmed: 33644404
Lancet. 2015 Jan 24;385(9965):351-61
pubmed: 25262344
N Engl J Med. 2019 Mar 14;380(11):1033-1042
pubmed: 30865797
Bioessays. 1994 Jul;16(7):519-24
pubmed: 7945281
Cell. 2016 Nov 17;167(5):1415-1429.e19
pubmed: 27863252
Elife. 2020 Aug 25;9:
pubmed: 32838838
Ann Oncol. 2020 May;31(5):641-649
pubmed: 32169310
Nat Genet. 2021 Oct;53(10):1415-1424
pubmed: 34594039
Nat Metab. 2022 Aug;4(8):967-969
pubmed: 35927356
PLoS Med. 2020 Mar 23;17(3):e1003062
pubmed: 32203549
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Diabetologia. 2020 Sep;63(9):1775-1782
pubmed: 32548700
Cell. 2020 Sep 3;182(5):1198-1213.e14
pubmed: 32888493
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Nat Commun. 2017 Oct 13;8(1):910
pubmed: 29030599
Int J Epidemiol. 2016 Dec 1;45(6):1961-1974
pubmed: 27616674
BMC Med. 2022 Sep 19;20(1):301
pubmed: 36117174
NPJ Genom Med. 2021 Oct 14;6(1):86
pubmed: 34650087
Front Genet. 2021 Jan 15;11:610852
pubmed: 33519914
Diabetes Care. 2022 Jan 1;45(1):232-240
pubmed: 34789503
Lancet. 2019 Aug 24;394(10199):697-708
pubmed: 31448741
N Engl J Med. 2016 Jun 2;374(22):2131-41
pubmed: 27192541
FASEB J. 2009 Apr;23(4):1072-80
pubmed: 19050047
Lancet Healthy Longev. 2021 Jun;2(6):e317-e326
pubmed: 34729547
Nat Med. 2020 Apr;26(4):542-548
pubmed: 32251405
Nat Commun. 2016 Mar 23;7:11122
pubmed: 27005778
Nat Commun. 2022 Apr 22;13(1):2198
pubmed: 35459240
Int J Epidemiol. 2023 Feb 8;52(1):71-86
pubmed: 35726641